Is an immune checkpoint inhibitor really a hopeless therapeutic choice for -mutant non-small cell lung cancer (NSCLC) patients?
作者信息
Kunimasa Kei, Nishino Kazumi, Kumagai Toru
机构信息
Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
出版信息
Ann Transl Med. 2019 Mar;7(Suppl 1):S32. doi: 10.21037/atm.2019.02.18.
Abstract
摘要
相似文献
1
Is an immune checkpoint inhibitor really a hopeless therapeutic choice for -mutant non-small cell lung cancer (NSCLC) patients?
Ann Transl Med. 2019 Mar;7(Suppl 1):S32. doi: 10.21037/atm.2019.02.18.
2
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.
Ther Adv Med Oncol. 2020 Jun 9;12:1758835920930333. doi: 10.1177/1758835920930333. eCollection 2020.
3
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821.
4
[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation
Treated by Immune Checkpoint Inhibitors].
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):641-648. doi: 10.3779/j.issn.1009-3419.2018.08.11.
5
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17.
6
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
Pharmacol Ther. 2017 Jun;174:1-21. doi: 10.1016/j.pharmthera.2017.02.001. Epub 2017 Feb 4.
7
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13.
8
[Combined Therapy with Targeted Drugs in Lung Cancer].
Gan To Kagaku Ryoho. 2016 Apr;43(4):413-8.
9
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Respir Res. 2019 Dec 2;20(1):270. doi: 10.1186/s12931-019-1244-2.
10
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis.
Oncotarget. 2019 Jan 4;10(2):209-215. doi: 10.18632/oncotarget.26541.
引用本文的文献
1
A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma.
Sci Rep. 2020 Apr 10;10(1):6214. doi: 10.1038/s41598-020-63200-7.
本文引用的文献
1
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
Lung Cancer. 2019 Jan;127:37-43. doi: 10.1016/j.lungcan.2018.11.021. Epub 2018 Nov 20.
2
Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.
Ann Transl Med. 2018 Nov;6(22):444. doi: 10.21037/atm.2018.10.24.
3
Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
Ann Oncol. 2018 Oct 1;29(10):2145-2147. doi: 10.1093/annonc/mdy312.
4
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.
J Thorac Oncol. 2018 Nov;13(11):1668-1675. doi: 10.1016/j.jtho.2018.07.016. Epub 2018 Jul 26.
5
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1.
6
Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations.
Ann Oncol. 2018 May 1;29(5):1331-1333. doi: 10.1093/annonc/mdy087.
7
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
Oncotarget. 2017 Dec 1;8(69):113807-113816. doi: 10.18632/oncotarget.22837. eCollection 2017 Dec 26.
8
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
JAMA Oncol. 2018 Feb 1;4(2):210-216. doi: 10.1001/jamaoncol.2017.4427.
9
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.
10
Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
J Thorac Oncol. 2017 Dec;12(12):1766-1778. doi: 10.1016/j.jtho.2017.07.032. Epub 2017 Aug 14.
Zotero 插件